ReviewDiscover oncology2025
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Human biomarker navigator.iMeta · 2026Review
- FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.Histopathology · 2026Article
- Article
- Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity.Case reports in dermatological medicine · 2026Article
- Immunological and inflammatory biomarkers of localized and locally advanced prostate cancer treated with radiotherapy.Frontiers in immunology · 2026Review
- Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second leading malignancy in males. Prostate cancer can be easily curable if it is diagnosed at an early stage. The prognosis of patients with metastatic or resistant cases can also be improved if adequately characterized with biomarkers. Prognostic and predictive biomarkers are crucial for the prediction of therapeutic response of prostate cancer patients. This article discusses various diagnostic, predictive, and prognostic biomarkers for this cancer. It also highlights the limitations of existing biomarkers and the challenges in novel biomarker discovery for prostate cancer. Moreover, this article emphasizes the application of genomics and epigenomics to discover novel prostate cancer biomarkers. Recent research to explore potential biomarkers for this disease has been reviewed here. Understanding the tumor immune microenvironment is vital for adequately diagnosing tumor tissues and predicting prognosis and therapeutic outcomes. Immune checkpoint markers are also discussed here. The current status of tumor microenvironment-based research for biomarker discovery has been explained in this article, highlighting its potential for novel biomarkers that can be employed in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.